All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2020-08-06T07:15:29.000Z

FDA grants BST-236 Fast Track designation for the treatment of older patients with AML

Aug 6, 2020
Share:

Bookmark this article

On August 4, 2020, the U.S. Food and Drug Administration (FDA) granted BST-236 (aspacytarabine) Fast Track designation for the treatment of acute myeloid leukemia (AML) in older patients (≥ 75 years) and in adult patients with comorbidities that make them unsuitable for intensive induction chemotherapy. The decision was based on the encouraging safety and efficacy data of the completed phase I/IIa study (NCT02544438) and the ongoing phase IIb study (NCT03435848).1 

Cytarabine has been used as the backbone of AML therapy for over 40 years due to its superior efficacy. However, it is associated with toxicities that significantly limit its use, especially in older and medically compromised patients, therefore, there is a significant unmet need to improve outcomes in these patient groups.

BST-236 (aspacytarabine) consists of cytarabine covalently bound to asparagine and acts as a pro-drug of cytarabine, thereby enabling high-dose therapy with lower systemic exposure to free cytarabine, which may help to reduce the toxicities normally associated with cytarabine1. BST-236 has been previously granted orphan drug designation by the FDA.

Phase I/IIa study (NCT02544438)3,4

  • Start/end: September 2015–September 2017
  • Open-label, uncontrolled, dose-escalation study to evaluate the safety and efficacy of BST-236 in 26 adult patients with newly diagnosed (ND) or relapsed/refractory AML or acute lymphoblastic leukemia who are older or unfit for intensive therapy
  • The median age was 76.5 years, with 84.6% of patients aged ≥ 70 years
  • BST-236 was administered intravenously (IV) once daily over 60 minutes for six consecutive days, in six dose-escalating cohorts (range, 0.3–6 g/m2 per day)

Results4

  • Maximum tolerated dose: 6 g/m2 per day
  •  BST-236 treatment was well tolerated
    • Grade 3 or higher treatment-emergent adverse events were mainly hematological or infection-related, such as febrile neutropenia (23%), pneumonia (20%), anemia (19%), thrombocytopenia (12%), and neutropenia (35%)
  • 30-day mortality was 30.7%
  • Overall response rate was 29.6%
    • A higher ORR (45.5%) was seen in the subgroup analysis for ND patients with AML, de novo, or secondary to myelodysplastic syndrome and unfit for standard induction
  • Median overall survival was 2.8 months in the entire population, 6.5 months in ND patients, and was not reached at 20 months in patients achieving complete remission

Phase IIb study (NCT03435848)5

  • Open-label, single arm, multicenter study to assess the efficacy and safety of BST-236 as a single agent in adults with ND AML who are not eligible for standard induction therapy due to advanced age or comorbidities
  • Estimated to enroll 65 patients
  • BTS-236 dosage:  4.5 g/m2 per day or 2.5 g/m2 per day, IV, for six days, with up to four courses of treatment (≤ two induction courses followed by ≤ two consolidation courses)
  • Study participation: 52 weeks, including treatment and follow-up periods

Primary outcome: Complete remission

  1. Biosight. Biosight granted U.S. FDA fast track designation for BST-236 for the treatment of acute myeloid leukemia. https://www.globenewswire.com/news-release/2020/08/04/2072449/0/en/Biosight-Granted-U-S-FDA-Fast-Track-Designation-for-BST-236-for-the-Treatment-of-Acute-Myeloid-Leukemia.html. Published Aug 4, 2020. Accessed Aug 5, 2020.
  2. Biosight. BST-236 (aspacytarabine). https://www.biosight-pharma.com/astarabine. Accessed Aug 5, 2020.
  3. Clinicaltrials.gov. Study evaluating the safety and efficacy of Astarabine in acute myeloid leukemia or acute lymphoblastic leukemia (BSTPHASE1-01). https://www.clinicaltrials.gov/ct2/show/record/NCT02544438. Updated Sep 9, 2017. Accessed Aug 5, 2020.
  4. Zuckerman T, Ram R, Akria L, et al. BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study. Blood Adv. 2019;3(22):3740-3749. DOI: 1182/bloodadvances.2019000468
  5. Clinicaltrials.gov. Efficacy and safety of BST-236 in newly diagnosed acute myeloid leukemia patients, unfit for standard induction therapy (ELPIS). https://www.clinicaltrials.gov/ct2/show/NCT03435848. Updated Jul 9, 2020. Accessed Aug 5, 2020.

Your opinion matters

Do you intend to implement next generation sequencing for measurable residual disease monitoring in AML patients?
0 votes - 5 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox